The NTIS website and supporting ordering systems are undergoing a major upgrade from 8PM on September 25th through approximately October 6. During that time, much of the functionality, including subscription and product ordering, shipping, etc., will not be available. You may call NTIS at 1-800-553-6847 or (703) 605-6000 to place an order but you should expect delayed shipment. Please do NOT include credit card numbers in any email you might send NTIS.
Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website http://www.gpo.gov/fdsys; (3) the federal government Internet portal USA.gov; or (4) a web search conducted using a commercial search engine such as http://www.google.com.
Accession Number ADA575854
Title WAVE3 is a Biomarker for Breast Cancer Progression and Metastasis.
Publication Date Jan 2013
Media Count 25p
Personal Author K. Sossey-Alaoui
Abstract About one-third of patients with cancer have metastases that are detected at the time their cancer is first diagnosed, and an additional third of patients have metastases that are too small to be detected by usual diagnostic tests. These micrometastases, however, will eventually grow into clinically significant metastases if the patient receives no treatment or local treatment of the primary tumor only. Metastatic breast cancer is a disease with low survival rates. The treatment of metastatic breast cancer involves the palliation of symptoms by reducing the tumor's size and growth rate. Currently, the effectiveness of therapy is determined by a series of tests. Imaging tests may include bone scan, radiograph, magnetic resonance imaging (MRI), and computed tomography (CT). Blood tests may include tumor markers, such as CA 27.29 and CA 15-3. The detection of circulating tumor cells has been proposed as a method to assess response to treatment of metastatic breast cancer. The detection of tumor cells may have clinical utility in risk stratification in early breast cancer, in early detection of relapse, and in monitoring the response to treatment. The circulating cells appear to have characteristics of tumor cells and may be identified in the peripheral blood of patients with cancer. The techniques that have been used to detect circulating tumor cells include cytometric and nucleic acid based approaches. The cytometric approaches use immunocytochemical methods to identify and characterize the individual tumor cells. Nucleic acid-based approaches detect the DNA and RNA sequences that are differentially expressed in tumor cells and normal blood components. The purpose of this study is to determine whether WAVE3, a metastasis promoter gene, can be used as a predictive marker for the progression and metastasis of breast cancer, using immunohistochemistry on human breast cancer tumors of different stages of breast cancer.
Keywords Blood analysis
Breast cancer
Chemotherapy
Circulating tumor cells
Cytometric acid based approaches
Detection
Diagnosis(General)
Diagnostic tests
Growth(General)
Images
Immunocytochemical methods
Immunostaining
Metastasis
Nucleic acids
Patients
Prognostic values
Therapy
Wave3 biomarkers


 
Source Agency Non Paid ADAS
NTIS Subject Category 57A - Anatomy
57S - Physiology
57E - Clinical Medicine
Corporate Author Cleveland Clinic Foundation, OH.
Document Type Technical report
Title Note Final rept. 1 Jun 2008 - 14 Dec 2012.
NTIS Issue Number 1319
Contract Number W81XWH-08-1-0236

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader